Holen Sie sich die Stockscreener-App
4.88
2.43%
0.15
Schlusskurs vom Vortag:
$4.73
Offen:
$4.79
24-Stunden-Volumen:
10,495
Relative Volume:
0.10
Marktkapitalisierung:
$46.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.44M
KGV:
-3.6402
EPS:
-1.3406
Netto-Cashflow:
$-7.72M
1W Leistung:
+1.79%
1M Leistung:
-8.06%
6M Leistung:
-32.14%
1J Leistung:
+99.38%
1-Tages-Spanne:
$4.74
$5.10
1-Wochen-Bereich:
$4.69
$5.10
52-Wochen-Spanne:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
4.845 | 45.60M | 0 | -10.44M | -7.72M | -1.3406 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.02 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.69 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Edesa Biotech Stock Price Forecast. Should You Buy EDSA? - StockInvest.us
Stonepine Capital Management, LLC Expands Edesa Biotech Inc (EDS - GuruFocus
Insider share moves at Edesa Biotech (EDSA) detailed in new SEC filing - Stock Titan
Velan Capital Investment Management LP Expands Edesa Biotech Inc (EDSA) Stake - GuruFocus
Edesa Biotech (EDSA) Dips 3.5% as Shares Test Key Support ZoneDay Trade Opportunities - dars.gov.et
EDSA Should I Buy - Intellectia AI
EDSA Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical-Stage InvestmentEPS Revision Trend - vinanet.vn
Stonepine group discloses sub-10% Edesa Biotech (NASDAQ: EDSA) position - Stock Titan
Velan Capital lifts Edesa Biotech (EDSA) stake to 9.99% with warrant leverage - Stock Titan
Edesa Biotech (NASDAQ: EDSA) major holder's multi-million-share stake detailed - Stock Titan
Edesa Biotech Enters Underwriting Deal With Guggenheim for $23.1M Equity Offering - TradingView
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech Prices $25 Million Stock-and-Warrant Offering to Fund Drug Pipeline - finance.biggo.com
Edesa Biotech Shares Tumble 13% on $25 Million Equity Offering - finance.biggo.com
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
Edesa (EDSA) Quarter in Focus: EPS Does Not Reach the Reported Estimate for the Current Session; Share Move - vinanet.vn
Edesa Biotech Stock Sinks After Fresh Capital Raise - TradingView
Edesa Biotech raises USD 25m to fuel vitiligo Phase II - AllSci
Edesa Biotech Raises $25 Million in Public Offering to Advance Immuno-Inflammatory Pipeline - TipRanks
Edesa Biotech prices $25M public offering at $5.50 per share By Investing.com - Investing.com Australia
Edesa Biotech prices $25M public offering at $5.50 per share - Investing.com Australia
Edesa Biotech Announces Pricing of $25.0 Million Public Offering - Yahoo Finance
Edesa Biotech stock tumbles on public offering launch By Investing.com - Investing.com Nigeria
Edesa Biotech Launches Public Offering of Common Shares, Warrants - marketscreener.com
Edesa Biotech Launches Public Offering to Fund Immuno-Inflammatory Pipeline - tipranks.com
Edesa Biotech launches public offering of common shares - Investing.com
Edesa Biotech launches public offering of common shares By Investing.com - Investing.com India
Edesa Biotech stock tumbles on public offering launch - Investing.com
Edesa Biotech Announces Proposed Public Offering of Common Shares and Warrants - Quiver Quantitative
Edesa Biotech Announces Proposed Public Offering - The Manila Times
Edesa Biotech(EDSA) Stock Options Chain | Quotes & News - Moomoo
Edesa Biotech Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
EDSA Q2 2026 Earnings: EPS Misses Consensus by 84.77% Despite Shares Rallying 5.61%Earnings Volatility Report - vinanet.vn
Brokers Set Expectations for Edesa Biotech FY2026 Earnings - MarketBeat
EDSA Q2 2026 Earnings: Wider-than-Expected Loss Amid Clinical-Stage SpendingShare Dilution Risk - vinanet.vn
EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal - Stocktwits
Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Edesa Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K EDESA BIOTECH For: 13 August By Investing.com - Investing.com South Africa
Edesa Biotech Q3 loss widens 140% to $5.4M on rising R&D spend - scanx.trade
Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens - Stock Titan
Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins - Quiver Quantitative
Edesa Starts Activating First Vitiligo Trial Sites as Enrollment Nears - Stock Titan
Edesa Biotech Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Edesa Biotech (EDSA) Rallies 5.34% as Shares Test Key Resistance at $5.80Volatility Breakout Picks - dars.gov.et
Edesa Biotech (EDSA) Edges Up 2.28% to $5.39 as Clinical-Stage Biotech Draws InterestRisk Reversal - dars.gov.et
Edesa Biotech (EDSA) to Post Earnings on Monday - MarketBeat
Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EDSA Q2 2026 Earnings: Wider Loss and 84.77% Negative Surprise Spotlight Pre-Revenue R&D Outlays - vinanet.vn
EDSA Q3'26 Earnings: EPS estimate is (0.43) USD - TradingView
Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units - Stock Titan
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):